Skip to main content

Acorda Value Stock - Dividend - Research Selection

Acorda Therapeutics

ISIN: US00484M6012, WKN: A2QLBW

Market price date: 19.05.2022
Market price: 0,55 USD

Acorda Therapeutics Fundamental data and company key figures of the share

Annual reports in USD
Key figures 21-03-2022
Cash flow
Net operating cash flow -41.348.000
Capital Expenditures -165.000
Free cash flow -41.513.000
Balance sheet
Total Equity 151.137.000
Liabilities & Shareholders equity 455.470.000
Income statement
Net income -103.954.000
Eps (diluted) -9,790
Diluted shares outstanding 10.621.000
Net sales/revenue 129.071.000

Fundamental ratios calculated on: 19-05-2022

Key figures 19-05-2022
Cash flow
P/C -0,14
P/FC -0,14
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization5.841.550,00 USD
CountryUnited States
IndicesNASDAQ Comp.,Russell 3000
Raw Data SourceUS GAAP in Millionen USD
Stock Split2021-01-04,1.000000/6.000000

Description of the company

Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to tackle the biggest pre-market stock movers for this morning as we get ready for trading hours to start on Thursday!

SEC filings reveal massive selling in media names, including Disney and Comcast

Leslie Picker joins the 'Halftime Report' to discuss what to expect from the SEC 13-F filings.

Acorda Therapeutics Reports First Quarter 2022 Financial Results - Corrected

ARDSLEY, N.Y. - Acorda Therapeutics, Inc. provided a business update and reported its financial results for the first quarter ended March 31, 2022.'Although Q1 over Q1 net sales decreased, we... | May 16, 2022

Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America

ARDSLEY, N.Y. & PANAMA CITY, May 11, 2022--Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America

Acorda Therapeutics Reports First Quarter 2022 Financial Results

ARDSLEY, N.Y., May 11, 2022--Acorda Therapeutics Reports First Quarter 2022 Financial Results

Acorda: Q1 Earnings Snapshot

ARDSLEY, N.Y. _ Acorda Therapeutics Inc. on Wednesday reported a loss of $25.6 million in its first quarter. The Ardsley, New York-based company said it had a loss of $1.93 per... | May 11, 2022

ACORDA THERAPEUTICS INC : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)

Item 2.02Results of Operations and Financial ConditionOn May 11, 2022, Acorda Therapeutics, Inc. issued a pressrelease announcing its financial performance for the first quarter ended March31,... | May 11, 2022

Acorda Therapeutics reports Q1 EPS ($1.66) vs. ($2.46) last year

Reports Q1 revenue $22.5M... ACOR

Acorda Therapeutics, Biopas agree to commercialize INBRIJA in Latin America

Acorda Therapeutics "... ACOR

Cable companies to offer effectively free internet to low-income homes

The news means that tens of millions of households could receive high-speed internet at no cost, according to the White House.